Loading...

co.don AG

CNWK.DEXETRA
Healthcare
Biotechnology
2.48
1.24(100.00%)

co.don AG (CNWK.DE) Company Profile & Overview

Explore co.don AG’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

co.don AG (CNWK.DE) Company Profile & Overview

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the minimally invasive repair of cartilage damage to knee joints following traumatic or degenerative defects. Its therapies include matrix-associated autologous cartilage transplantation, a biological therapy for the treatment of damaged articular cartilage with the body's own cells; and autologous chondrocyte transplantation for the regeneration of biomechanical load-bearing and pressure-resistant cartilage tissue. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.

SectorHealthcare
IndustryBiotechnology
CEODipl.-Kfm. Dirk Hessel

Contact Information

49332843460
Warthestrasse 21, Teltow

Company Facts

120 Employees
IPO DateFeb 1, 2001
CountryDE

Frequently Asked Questions

;